Dr. Fred Schumacher is Associate Professor in the Department of Population and Quantitative Health Sciences and Faculty in the Cleveland Institute for Computational Biology, both at Case Western Reserve University. Dr. Schumacher is also Co-Leader of the Cancer Prevention Control & Population Research Program as part of the Case Comprehensive Cancer Center. His primary research focus is on cancer, particularly prostate cancer. As an investigator and leader in several major international consortium, Dr. Schumacher has
- Identified multiple novel genomic regions associated with prostate, testicular and breast cancer, representing discoveries based on incorporating genome-wide association studies (GWAS) with cancer epidemiology
- Expanded the use of GWAS through combined studies of varying design, providing the power to evaluate candidate gene pathways, incorporate related biomarkers, and assess cancer sub-types
- Explored the potential biological overlap of complex traits and conditions (such as diabetes) with cancer, providing a better understanding of the cancer initiation process and highlighting several areas for potential disease risk reduction.
- Developed and implemented polygenic risk scores to improve screening modalities and treatment paradigms
- McManus, JM, Vargas, R, Bazeley, PS, Schumacher, FR, Sharifi, N. Association Between Adrenal-Restrictive HSD3B1 Inheritance and Hormone-Independent Subtypes of Endometrial and Breast Cancer. JNCI Cancer Spectr 2022; 6 (5): . PubMed PMID:35947687 PubMed Central PMC9475354.
- Arenas-Gallo, C, Owiredu, J, Weinstein, I, Lewicki, P, Basourakos, SP, Vince, R Jr, Al Hussein Al Awamlh, B, Schumacher, FR, Spratt, DE, Barbieri, CE et al.. Race and prostate cancer: genomic landscape. Nat Rev Urol 2022; 19 (9): 547-561. PubMed PMID:35945369 .
- Isali, I, McClellan, P, Wong, TR, Sun, C, Stout, AC, Schumacher, FR, Markt, S, Wilfred Wu, CH, Penney, KL, El-Nashar, S et al.. A systematic review and in silico study of potential genetic markers implicated in cases of overactive bladder. Am J Obstet Gynecol 2022; : . PubMed PMID:35932882 .
- Miller, AK, Gordon, JC, Curtis, JW, Ajayakumar, J, Schumacher, FR, Avril, S. The Geographic Context of Racial Disparities in Aggressive Endometrial Cancer Subtypes: Integrating Social and Environmental Aspects to Discern Biological Outcomes. Int J Environ Res Public Health 2022; 19 (14): . PubMed PMID:35886465 PubMed Central PMC9320863.
- Markt, SC, Booker, BD, Bensken, W, Schiltz, NK, Schumacher, FR, Rose, J, Cooper, G, Selfridge, JE, Koroukian, SM. Sociodemographic and clinical factors associated with receipt of biomarker testing in patients with metastatic colorectal cancer. Cancer Med 2022; : . PubMed PMID:35837788 .
- Khalifa, AO, Isali, I, Celik, H, Mastran, M, McClellan, P, Gillespie, C, Shankar, S, MacLennan, GT, Anderson, JM, Schumacher, FR et al.. A preliminary evaluation of in vivo response to a filament-wound macroporous collagen midurethral sling in an ovine model. J Biomed Mater Res B Appl Biomater 2022; : . PubMed PMID:35779040 .
- Watts, EL, Perez-Cornago, A, Fensom, GK, Smith-Byrne, K, Noor, U, Andrews, CD, Gunter, MJ, Holmes, MV, Martin, RM, Tsilidis, KK et al.. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. Int J Epidemiol 2022; : . PubMed PMID:35726641 .
- Morales Berstein, F, McCartney, DL, Lu, AT, Tsilidis, KK, Bouras, E, Haycock, P, Burrows, K, Phipps, AI, Buchanan, DD, Cheng, I et al.. Assessing the causal role of epigenetic clocks in the development of multiple cancers: a Mendelian randomization study. Elife 2022; 11 : . PubMed PMID:35346416 PubMed Central PMC9049976.
- Markt, SC, Penney, KL, Schumacher, FR. Finding a Place for Family History To Inform High-grade Prostate Cancer Risk. Eur Urol 2022; 82 (2): 170-171. PubMed PMID:35105480 .
- Schumacher, FR, Basourakos, SP, Lewicki, PJ, Vince, R, Spratt, DE, Barbieri, CE, Shoag, JE. Race and Genetic Alterations in Prostate Cancer. JCO Precis Oncol 2021; 5 : . PubMed PMID:34746633 PubMed Central PMC8563071.